戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 esity (odds ratio, 2.4 [95% CI: 1.1, 5.4] or morbid obesity).
2  hepatic fibrosis in patients with severe to morbid obesity.
3 a spectrum of NAFLD that may prelude NASH in morbid obesity.
4    Deficiency of either leptin or LRb causes morbid obesity.
5 fter gastric bypass surgery for treatment of morbid obesity.
6 aused by hepatic pathology that results from morbid obesity.
7 ctive primary procedure for the treatment of morbid obesity.
8 on following gastric restrictive surgery for morbid obesity.
9 BPD) has been advocated for the treatment of morbid obesity.
10 tive procedure for the surgical treatment of morbid obesity.
11  and effective approach for the treatment of morbid obesity.
12 utations in the leptin receptor gene develop morbid obesity.
13 Alterations in Arg metabolism are present in morbid obesity.
14 astrectomies performed on 6915 patients with morbid obesity.
15 d SG (NRASG) over two years in patients with morbid obesity.
16 ing postoperative outcomes in primary SG for morbid obesity.
17 t mechanisms of cardiovascular protection in morbid obesity.
18 ]) for the classification of liver injury in morbid obesity.
19 tical eligibility criteria for patients with morbid obesity.
20 n increasingly popular form of treatment for morbid obesity.
21 astric bypass surgery-induced weight loss in morbid obesity.
22 syndrome (IBS) is prevalent in patients with morbid obesity.
23 routine coverage for SG for the treatment of morbid obesity.
24 c fat using 3T magnetic resonance imaging in morbid obesity.
25 nd db/db mice in the absence of diabetes and morbid obesity.
26 receptor-deficient (db/db) mice that develop morbid obesity.
27 ral tissue, but this capacity decreases with morbid obesity.
28 festyle changes alone in treating adolescent morbid obesity.
29 based on the complicating issues surrounding morbid obesity.
30 tes in patients who do not meet criteria for morbid obesity.
31 in 48 of 1282 patients (3.7%) after RYGB for morbid obesity.
32 , and may have implications for treatment of morbid obesity.
33  patients with gastric motility disorders or morbid obesity.
34  in the ob gene causes leptin deficiency and morbid obesity.
35 f death increased 7.4 times in patients with morbid obesity.
36 in 48 of 904 patients (5.3%) after RYGBP for morbid obesity.
37 ldhood obesity (P = 0.0003) and common adult morbid obesity (0.0003 < P < 0.007).
38 egion in 3q29; we designated this region the morbid obesity 1 (MO1) locus.
39  of overweight (39.8%), obesity (26.6%), and morbid obesity (3.6%) were similar in most geographic lo
40 rdized difference, 0.17); had lower rates of morbid obesity (4.8% vs 7.6%; standardized difference, 0
41 of obstruction following gastric surgery for morbid obesity, 50% experienced relief of symptoms follo
42                                              Morbid obesity added 48 minutes to OT (P = 0.018), 1.1 u
43                                              Morbid obesity-adjusted rates of surgery were then calcu
44         The trial enrolled 240 patients with morbid obesity aged 18 to 60 years who were randomized t
45                                              Morbid obesity alters drug dose requirement and time cou
46  the prevalence and clinical implications of morbid obesity among patients undergoing PCI.
47  the prevalence and clinical implications of morbid obesity among patients undergoing percutaneous co
48 t effective method to curtail the effects of morbid obesity and all of its comorbid conditions.
49 iary protein CEP19 in humans and mice causes morbid obesity and defines a target for investigating th
50 tory markers and serotonergic dynamics in co-morbid obesity and depression.
51  of leukocyte activation and inflammation in morbid obesity and diabetes and diminish with weight los
52 tations of leptin or leptin receptor develop morbid obesity and diabetes.
53 re defective in leptin signaling and develop morbid obesity and diabetes.
54  holds promise as a therapeutic strategy for morbid obesity and diabetes.
55 ion of inflammation resolution prevents from morbid obesity and hyperglycemia under dietary overload
56        Leptin-deficient mice (ob/ob) exhibit morbid obesity and insulin resistance.
57 f the most commonly performed operations for morbid obesity and is associated with significant long-t
58  considered the most effective treatment for morbid obesity and its comorbidities; however, a systema
59 ective in the treatment of fully established morbid obesity and its endocrine and metabolic consequen
60  device may be suitable for the treatment of morbid obesity and its related comorbidities.
61 ith reduced energy expenditure, resulting in morbid obesity and leptin resistance.
62 erformed in liver transplant recipients with morbid obesity and may lead to weight loss, correction o
63 f the most efficient procedures for treating morbid obesity and results in weight-loss and improvemen
64  is a reasonable choice for the treatment of morbid obesity and should be covered by both public and
65                                Patients with morbid obesity and T2DM demonstrated high levels of live
66 at macrophages in WAT play an active role in morbid obesity and that macrophage-related inflammatory
67 (LAMB3) gene showing strong association with morbid obesity and thereby risk of type 2 diabetes.
68 rt were patients with a primary diagnosis of morbid obesity and who underwent laparoscopic Roux-en-Y
69            For type 2 diabetes, moderate and morbid obesity, and for both the Q121 and three-marker h
70                Baseline depressive symptoms, morbid obesity, and intensive care unit benzodiazepine d
71 sm, nonalcoholic steatohepatitis (NASH), and morbid obesity, and may contribute to liver disease.
72 y for patients with history of neck surgery, morbid obesity, and ongoing anticoagulation therapy.
73 nsity and angiogenic capacity decreased with morbid obesity, and subcutaneous, but not visceral, adip
74                                   Severe and morbid obesity are still relatively rare in France, with
75 epresent what we believe is a novel model of morbid obesity associated with an improved metabolic pro
76 rtension, congenital cyanotic heart disease, morbid obesity associated with sleep apnea syndrome, sic
77                          Paradoxically, even morbid obesity associates with better outcomes in studie
78  switch as the primary surgical treatment of morbid obesity at a single institution during the 10-yea
79 ix of the remaining patients have persistent morbid obesity at least 2 years after surgery but refuse
80 ino acid changes, are null mutations causing morbid obesity, because homozygotes for the variant sequ
81 optimizing comorbidities such as smoking and morbid obesity before ventral and incisional hernia repa
82 oux-en-Y gastric bypass for the treatment of morbid obesity between 1999 and 2002 (n = 24,166).
83 ry laparoscopic gastric bypass operation for morbid obesity between May 1, 2007, and September 30, 20
84 nfidence interval (CI): 1.14, 3.20), whereas morbid obesity (BMI >/= 40) was suggestive of increased
85 cant predictors of a wound complication were morbid obesity (BMI >30), having had a MT, low preoperat
86 rother had RP, PAP, mild mental retardation, morbid obesity (BMI >50 and 37, respectively), lobulated
87                             BMI>31 indicates morbid obesity, BMI>27 indicates >20% over ideal body we
88                                              Morbid obesity (body mass index > or =40 kg/m(2)) is an
89                We examined the prevalence of morbid obesity (body mass index [BMI] >/= 40 kg/m(2)) am
90 nts who do not meet body weight criteria for morbid obesity (body mass index [BMI], <35 kg/m), but la
91 ic bypass is a highly successful approach to morbid obesity but results in significant perioperative
92 obese controls and accounted for 0.7% of our morbid obesity cases (body mass index (BMI) >or= 40 kg m
93                                              Morbid Obesity Centre, Vestfold Hospital Trust.
94 among individuals with obesity (class I) and morbid obesity (class II/III).
95 ass is the procedure of choice when GERD and morbid obesity coexist.
96 age points) also was observed in adults with morbid obesity compared with normal-weight controls.
97      The number of patients with obesity and morbid obesity continues to increase.
98 term (<2 years) efficacy of RYGB surgery for morbid obesity, corroborated by meta-analytic techniques
99 18-month-old female child who presented with morbid obesity, decreased linear growth, and reversal of
100  Leptin deficiency in mice and humans causes morbid obesity, diabetes, and various neuroendocrine ano
101 past year have focused on three broad areas: morbid obesity, gastric cancer, and peptic ulcer disease
102 ic gastric banding as a primary treatment of morbid obesity has been widely accepted, the effects of
103                                              Morbid obesity has no clinically significant impact on t
104                            The prevalence of morbid obesity has risen sharply in recent years, even a
105  Roux-en-Y gastric bypass (RYGB) surgery for morbid obesity in a large nationwide cohort.
106               The prevalence of obesity, and morbid obesity in particular, continues to rise rapidly
107 ght to evaluate the prognostic impact of pre-morbid obesity in patients with HF.
108 gnificantly lower than the observed rates of morbid obesity in the general population in 3 regions.
109 eillance System data to explore the rates of morbid obesity in the general population of each UNOS re
110 ency coding variant that was associated with morbid obesity in the LAMB3 gene.
111 shift in the type of procedure performed for morbid obesity in the United States toward sleeve gastre
112                                              Morbid obesity induces adipose stem cell (ASC) shortage
113 d duodenal switch procedure as performed for morbid obesity involves a 75% subtotal greater curvature
114                                              Morbid obesity is a barrier to kidney transplantation du
115                                              Morbid obesity is a global health epidemic.
116                                              Morbid obesity is also associated with an increased risk
117                                              Morbid obesity is an epidemic in the United States and p
118                                              Morbid obesity is associated with higher mortality on th
119                                              Morbid obesity is associated with unacceptable high recu
120               Although the predisposition to morbid obesity is heritable, the identities of the disea
121                                              Morbid obesity is increasing in prevalence among patient
122    The number of bariatric interventions for morbid obesity is increasing worldwide.
123                                              Morbid obesity is increasingly becoming a major public h
124  frequently used and effective treatment for morbid obesity is Roux-en-Y gastric bypass surgery (RYGB
125 94 to 2003 was performed using the key words morbid obesity, laparoscopy, bariatric surgery, pneumope
126                    The surgical treatment of morbid obesity leads to dramatic improvement in the como
127                                              Morbid obesity may be accompanied by diabetes and painfu
128 tractable weight gain associated with severe morbid obesity, multiple endocrine abnormalities and mem
129 gn pathology (n = 48) and gastric bypass for morbid obesity (n = 40) were assessed.
130 tructive lung disease (overlap syndrome) and morbid obesity (obesity hypoventilation syndrome) increa
131                                              Morbid obesity occurs frequently in patients with renal
132  and differing socio-cultural perceptions of morbid obesity on racial disparities.
133 n therapy (OR, 0.80; 95% CI, 0.56-1.14), and morbid obesity (OR, 0.94; 95% CI, 0.74-1.19) were not as
134 n therapy (OR, 1.74; 95% CI, 1.29-2.36), and morbid obesity (OR, 1.54; 95% CI, 1.24-1.92) were associ
135 though some individual offspring suffer from morbid obesity, others escape the malprogramming.
136 lated donor nephrectomy, gastric banding for morbid obesity, partial gastrectomy, and various other p
137                                              Morbid obesity predicted higher post-LT mortality before
138                                  The rise in morbid obesity presents diagnostic challenges in compute
139 pproximately 1% of eligible individuals with morbid obesity receive bariatric surgery.
140  P = 0.46 for type 2 diabetes, moderate, and morbid obesity, respectively).
141 elucidating the key networks associated with morbid obesity, response to RYGB, and disease as a whole
142  in leptin-deficient adults with established morbid obesity results in profound weight loss, increase
143 ed by infantile hypotonia, short stature and morbid obesity, results from deficiencies in multiple ge
144                 As the number of people with morbid obesity rises, so will the number of bariatric pr
145                                 In addition, morbid obesity's impact on many organ systems decreases
146         This phenotype closely resembles the morbid obesity seen in humans.
147  Roux-en-Y gastric bypass, in the Adolescent Morbid Obesity Surgery (AMOS) study.
148     Here, we describe an autosomal-recessive morbid-obesity syndrome and identify the disease-causing
149 th null mutations in a single gene producing morbid obesity, the new models develop a more moderate o
150                          Among patients with morbid obesity, the use of vagal nerve block therapy com
151  Medline search using "perioperative care," "morbid obesity," "thromboembolic complications," "preope
152  adhere to practice guidelines that consider morbid obesity to be a contraindication to liver transpl
153 cantly lower in morbidly obese patients, and morbid obesity was an independent predictor of mortality
154           A NASH Clinical Scoring System for Morbid Obesity was derived to predict the probability of
155 sence of 5 conditions commonly comorbid with morbid obesity were examined for morbidly obese patients
156                                Patients with morbid obesity were included at two obesity centers in S
157                          The relationship of morbid obesity with LT outcomes and survival benefit in
158 4; P = 8.1 x 10-4) and, in another analysis, morbid obesity (z score = 3.8; P = 1.3 x 10-4).

 
Page Top